Cargando…
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Methotrexate (MTX), the primary treatment for the articular-type juvenile idiopathic arthritis (JIA), is effective and brings about radiological improvement. Patient compliance is good, and it is recognized that its known side effects, namely, disruption of liver function and induction of pulmonary...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638602/ https://www.ncbi.nlm.nih.gov/pubmed/18815725 http://dx.doi.org/10.1007/s10165-008-0123-3 |
_version_ | 1782164413206233088 |
---|---|
author | Mori, Masaaki Naruto, Takuya Imagawa, Tomoyuki Murata, Takuji Takei, Syuji Tomiita, Minako Itoh, Yasuhiko Fujikawa, Satoshi Yokota, Shumpei |
author_facet | Mori, Masaaki Naruto, Takuya Imagawa, Tomoyuki Murata, Takuji Takei, Syuji Tomiita, Minako Itoh, Yasuhiko Fujikawa, Satoshi Yokota, Shumpei |
author_sort | Mori, Masaaki |
collection | PubMed |
description | Methotrexate (MTX), the primary treatment for the articular-type juvenile idiopathic arthritis (JIA), is effective and brings about radiological improvement. Patient compliance is good, and it is recognized that its known side effects, namely, disruption of liver function and induction of pulmonary lesions, are unlikely to be severe at the low MTX doses that are administered. In Japan, MTX was granted approval in 1999 by the then Ministry of Health and Welfare specifically for treating rheumatoid arthritis in adult patients, allowing it be generally used in medical institutions for patients having National Health Insurance. However, in the pediatric field, its use outside the indications has so far been unavoidable, and has been left to the discretion of the physician. Finally, at the present conference, expansion of the indications of MTX for JIA was approved in Japan. It is noteworthy that this expansion of indications was achieved without requiring clinical trials on children sponsored by the pharmaceutical company: it was achieved rather by collecting necessary information through ongoing efforts (including collection and analysis of information about approval status in foreign countries, adequate evidence from the literature, implementation of a clinical use survey in Japan, etc.). It also merits attention that the maximum dose (10 mg/m(2)) was set on the basis of pharmacokinetic data from children, rather than relying on the dosing method and dose for adults. |
format | Text |
id | pubmed-2638602 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-26386022009-02-11 Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan Mori, Masaaki Naruto, Takuya Imagawa, Tomoyuki Murata, Takuji Takei, Syuji Tomiita, Minako Itoh, Yasuhiko Fujikawa, Satoshi Yokota, Shumpei Mod Rheumatol Review Article Methotrexate (MTX), the primary treatment for the articular-type juvenile idiopathic arthritis (JIA), is effective and brings about radiological improvement. Patient compliance is good, and it is recognized that its known side effects, namely, disruption of liver function and induction of pulmonary lesions, are unlikely to be severe at the low MTX doses that are administered. In Japan, MTX was granted approval in 1999 by the then Ministry of Health and Welfare specifically for treating rheumatoid arthritis in adult patients, allowing it be generally used in medical institutions for patients having National Health Insurance. However, in the pediatric field, its use outside the indications has so far been unavoidable, and has been left to the discretion of the physician. Finally, at the present conference, expansion of the indications of MTX for JIA was approved in Japan. It is noteworthy that this expansion of indications was achieved without requiring clinical trials on children sponsored by the pharmaceutical company: it was achieved rather by collecting necessary information through ongoing efforts (including collection and analysis of information about approval status in foreign countries, adequate evidence from the literature, implementation of a clinical use survey in Japan, etc.). It also merits attention that the maximum dose (10 mg/m(2)) was set on the basis of pharmacokinetic data from children, rather than relying on the dosing method and dose for adults. Springer Japan 2008-09-25 2009-02 /pmc/articles/PMC2638602/ /pubmed/18815725 http://dx.doi.org/10.1007/s10165-008-0123-3 Text en © Japan College of Rheumatology 2008 |
spellingShingle | Review Article Mori, Masaaki Naruto, Takuya Imagawa, Tomoyuki Murata, Takuji Takei, Syuji Tomiita, Minako Itoh, Yasuhiko Fujikawa, Satoshi Yokota, Shumpei Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan |
title | Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan |
title_full | Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan |
title_fullStr | Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan |
title_full_unstemmed | Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan |
title_short | Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan |
title_sort | methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for jia indication in japan |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2638602/ https://www.ncbi.nlm.nih.gov/pubmed/18815725 http://dx.doi.org/10.1007/s10165-008-0123-3 |
work_keys_str_mv | AT morimasaaki methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT narutotakuya methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT imagawatomoyuki methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT muratatakuji methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT takeisyuji methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT tomiitaminako methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT itohyasuhiko methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT fujikawasatoshi methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan AT yokotashumpei methotrexateforthetreatmentofjuvenileidiopathicarthritisprocesstoapprovalforjiaindicationinjapan |